
ZURA Stock Forecast & Price Target
ZURA Analyst Ratings
Bulls say
Zura Bio is a clinical-stage biotechnology company with promising product candidates targeting autoimmune and inflammatory diseases. Analysts believe that the dual anti-IL-17 and anti-BAFF activity of Tibulizumab could provide greater benefits than current therapies, and that the company has taken steps to minimize variability between trial sites. Tibulizumab has shown potential for strong sales in Hidradenitis Suppurativa, a condition with a significant unmet need, and is expected to be priced competitively with other biologics in the space. The company has a strong cash position and a seasoned management team, with potential for significant future milestones and royalties from partnerships. However, risks include potential intellectual property challenges and stock price volatility due to market dynamics.
Bears say
Zura Bio is facing significant challenges in the development and commercialization of their novel medicines for autoimmune and inflammatory diseases. Despite promising assets in their pipeline, the company faces risks related to funding and competition, as well as uncertainties in the understanding and treatment of these complex diseases. Their expected results in late 2026 may be delayed or not meet expectations, resulting in a negative outlook for the stock.
This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares